Changing interim monitoring in response to internal clinical trial data
Changing interim monitoring in response to internal clinical trial data
ABSTRACT Designing clinical trials for emerging infectious diseases such as COVID-19 is challenging because information needed for proper planning may be lacking. Pre-specified adaptive designs can be attractive options, but what happens if a trial with no such design needs to be modified? For example, unexpectedly high efficacy (approximately 95%) …